石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01093 石药集团

未开盘 12-19 16:08:06

8.200

+0.190

+2.37%

最高8.380	最低7.990	成交量2.00亿
今开8.000	昨收8.010	日振幅4.87%
总市值944.80亿	流通市值944.80亿	总股本115.22亿
成交额16.41亿	换手率1.73%	流通股本115.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":8.2,"timestamp":1766131686004,"preClose":8.01,"halted":0,"volume":199797151,"delay":0,"floatShares":11522000000,"shares":11522000000,"eps":0.4078514968948933,"marketStatus":"未开盘","change":0.19,"latestTime":"12-19 16:08:06","open":8,"high":8.38,"low":7.99,"amount":1641156658,"amplitude":0.048689,"askPrice":8.21,"askSize":354000,"bidPrice":8.2,"bidSize":522000,"shortable":3,"etf":0,"ttmEps":0.3918424202711326,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":0,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":8.01,"dividendRate":0.030724,"openAndCloseTimeList":[[1766107800000,1766116800000],[1766120400000,1766131200000]],"volumeRatio":1.7180137981793622,"optionData":{"bulkOrders":[{"symbol":"CSP.HK","call":false,"expireDate":1774800000000,"strike":"7.00","timestamp":1766124403763,"price":0.23,"volume":250,"amount":115000,"type":"*"},{"symbol":"CSP.HK","call":false,"expireDate":1772035200000,"strike":"7.00","timestamp":1766121204074,"price":0.13,"volume":250,"amount":65000,"type":"*"}]},"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.4255,"impliedVolPercentile":0.2927},"requestUrl":"/m/hq/s/01093","defaultTab":"news","newsList":[{"id":"2593129901","title":"石药集团高层人事调整：“二代”蔡磊接棒CEO，与魏青杰共同出任副主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2593129901","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593129901?lang=zh_cn&edition=full","pubTime":"2025-12-21 16:19","pubTimestamp":1766305154,"startTime":"0","endTime":"0","summary":"石药集团（01093）发布公告，自2025年12月19日起，董事会进行了高层人事调整。张翠龙因工作调动不再担任副主席、首席执行官及授权代表，但仍将继续担任执行董事。蔡磊获委任为副主席、执行董事、首席执行官及授权代表，魏青杰获委任为副主席、执行董事及首席运营官。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512213597583055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1813983027.USD","IE00BZ08YS42.EUR","SG9999004220.SGD","LU0501845795.SGD","LU1226287529.USD","LU1328277881.USD","01093","LU1152091168.USD","BK1521","LU1993786604.SGD","HK0000165453.HKD","LU0880133367.SGD","LU1152091754.HKD","LU2039709279.SGD","IE0008369823.USD","LU1226287875.USD","LU0067412154.USD","IE00B543WZ88.USD","IE0008368742.USD","IE00BZ08YR35.GBP","LU1226288170.HKD","IE00B031HY20.USD","IE00BZ08YT58.USD","LU1226287792.SGD","IE00B5MMRT66.SGD","LU0315179316.USD","LU1226288253.USD","LU0314109678.HKD","LU1008478684.HKD","LU0140636845.USD","LU1951186391.HKD","BK1515","LU1960683339.HKD","BK1191","LU0326950275.SGD","LU0072913022.USD","LU1807302812.USD"],"gpt_icon":0},{"id":"2592101071","title":"石药集团任命蔡为新任领导，正处于领导层过渡期CSPC Pharmaceutical Group Appoints Cai as New Head Amid Leadership Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2592101071","media":"动脉网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592101071?lang=zh_cn&edition=full","pubTime":"2025-12-20 15:33","pubTimestamp":1766215980,"startTime":"0","endTime":"0","summary":"by GOAI由GOAI生成Share To分享到CSPC Pharmaceutical Group has announced leadership changes, with Cai taking over as head of the company, succeeding Zhang. The transition marks a significant shift in the organization’s management structure. CSPC, a major player in the pharmaceutical industry, has not disclosed further details regarding the reasons behind this change or any strategic implications tied to the leadership transition..石药集团宣布了领导层的变动，蔡接替张成为公司的负责人。In addition to CSPC’s announcement, several other updates have emerged across the biotech and pharmaceutical sectors. ProFound and Nona have hired leaders specializing in artificial intelligence as part of their efforts to integrate AI into their operations. PureTech Health, BeOne, Breyer Capital, and NanOlogy LLC have also reported developments within their organizations.除了石药集团的公告外，生物技术和制药行业还出现了几项其他更新。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220153620a462e76b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220153620a462e76b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","LU0880133367.SGD","LU0072913022.USD","LU1807302812.USD","LU0314109678.HKD","01093","IE00B031HY20.USD","LU1226288253.USD","LU1226288170.HKD","IE00BZ08YT58.USD","HK0000165453.HKD","LU1951186391.HKD","LU1226287792.SGD","LU1813983027.USD","LU1226287875.USD","SG9999004220.SGD","LU0315179316.USD","LU2039709279.SGD","LU1328277881.USD","LU1960683339.HKD","LU0140636845.USD","IE00B5MMRT66.SGD","LU0501845795.SGD","LU1993786604.SGD","LU1152091754.HKD","IE0008369823.USD","LU1152091168.USD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","IE0008368742.USD","BK1521","BK1191","LU0067412154.USD","IE00BZ08YR35.GBP","LU0326950275.SGD","LU1226287529.USD","LU1008478684.HKD"],"gpt_icon":0},{"id":"2592110481","title":"石药集团CEO换人，蔡磊获委任为副主席及执行董事等职","url":"https://stock-news.laohu8.com/highlight/detail?id=2592110481","media":"CPHI制药在线","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592110481?lang=zh_cn&edition=full","pubTime":"2025-12-20 15:30","pubTimestamp":1766215851,"startTime":"0","endTime":"0","summary":"公告显示，为石药集团服务多年的“老将”张翠龙因工作调动，卸任董事会副主席、首席执行官及授权代表职务，但仍将留任执行董事。此次卸任的CEO张翠龙自1996年加入石药集团，并于2018年获委任为执行董事；2019年担任副主席、轮值行政总裁；2022年委任为行政总裁，一路见证了石药集团的重要发展阶段。新任CEO蔡磊则是石药集团董事会主席、执行董事及主要股东蔡东晨之子，也是执行董事蔡鑫的胞兄。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220153406a462e64c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220153406a462e64c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1328277881.USD","LU0314109678.HKD","IE00BZ08YS42.EUR","LU2039709279.SGD","LU1008478684.HKD","LU1152091168.USD","LU0067412154.USD","LU1807302812.USD","LU1226288253.USD","LU0880133367.SGD","IE00BZ08YT58.USD","IE00B5MMRT66.SGD","IE0008369823.USD","LU1226288170.HKD","IE00BZ08YR35.GBP","IE00B543WZ88.USD","LU0072913022.USD","LU1226287529.USD","LU1152091754.HKD","BK1191","LU1226287875.USD","LU1813983027.USD","LU1960683339.HKD","01093","LU1951186391.HKD","BK1515","IE0008368742.USD","LU1993786604.SGD","SG9999004220.SGD","LU0326950275.SGD","HK0000165453.HKD","IE00B031HY20.USD","BK1521","LU0315179316.USD","LU0140636845.USD","LU0501845795.SGD","LU1226287792.SGD"],"gpt_icon":0},{"id":"2592162178","title":"石药集团(01093)：SYH2085片在中国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2592162178","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592162178?lang=zh_cn&edition=full","pubTime":"2025-12-19 21:17","pubTimestamp":1766150269,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的SYH2085片已获得中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。本次获批的临床适应症为用于治疗成人及12岁以上青少年单纯性甲型和乙型流感。该产品有望成为治疗流感的有效药物，具有较高的临床开发价值，并将进一步丰富集团在抗感染治疗领域的产品管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226288253.USD","LU0315179316.USD","SG9999004220.SGD","LU0326950275.SGD","LU1328277881.USD","BK1515","LU0880133367.SGD","IE00BZ08YR35.GBP","01093","IE00BZ08YT58.USD","LU0072913022.USD","LU0501845795.SGD","LU1226287792.SGD","LU1807302812.USD","LU1993786604.SGD","IE00B5MMRT66.SGD","LU0314109678.HKD","LU1008478684.HKD","BK1191","HK0000165453.HKD","LU1960683339.HKD","IE00BZ08YS42.EUR","BK1521","LU1152091168.USD","IE00B543WZ88.USD","LU1951186391.HKD","LU2039709279.SGD","IE00B031HY20.USD","IE0008368742.USD","LU1226288170.HKD","LU1226287875.USD","LU1813983027.USD","IE0008369823.USD","LU1152091754.HKD","LU1226287529.USD","LU0140636845.USD","LU0067412154.USD"],"gpt_icon":0},{"id":"2592316211","title":"石药集团(01093)：魏青杰获委任为副主席、公司执行董事及首席运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=2592316211","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592316211?lang=zh_cn&edition=full","pubTime":"2025-12-19 21:14","pubTimestamp":1766150083,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)发布公告，自2025年12月19日起生效：张翠龙先生因工作调动而不再担任董事会副主席、公司首席执行官及根据香港联合交易所有限公司证券上市规则第3.05条项下公司授权代表，但将继续担任公司执行董事;蔡磊博士获委任为副主席、公司执行董事、首席执行官及授权代表;魏青杰先生获委任为副主席、公司执行董事及首席运营官。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"石药集团(01093)：魏青杰获委任为副主席、公司执行董事及首席运营官","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0314109678.HKD","IE0008368742.USD","IE00B031HY20.USD","SG9999004220.SGD","LU1813983027.USD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU0501845795.SGD","LU0140636845.USD","IE0008369823.USD","LU1008478684.HKD","LU1807302812.USD","IE00BZ08YR35.GBP","LU2039709279.SGD","LU0315179316.USD","HK0000165453.HKD","LU1152091168.USD","BK1191","BK1521","LU1226288170.HKD","LU1152091754.HKD","LU1226287792.SGD","LU0880133367.SGD","LU0072913022.USD","LU0067412154.USD","LU1960683339.HKD","BK1515","LU1328277881.USD","LU1226288253.USD","LU1993786604.SGD","LU1951186391.HKD","IE00BZ08YT58.USD","IE00B543WZ88.USD","LU1226287529.USD","IE00BZ08YS42.EUR","01093","LU1226287875.USD"],"gpt_icon":0},{"id":"2592115387","title":"石药集团12月19日获主力大幅加仓1.2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592115387","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592115387?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:15","pubTimestamp":1766132132,"startTime":"0","endTime":"0","summary":"12月19日, 石药集团股价涨2.37%，报收8.20元，成交金额16.4亿元，换手率1.73%，振幅4.87%，量比1.71。石药集团今日主力资金净流入1.2亿元，连续4日净流入，上一交易日主力净流入5814.3万元。近一年数据显示，该股主力连续4日净流入后，次日上涨概率为57.14%，平均涨幅为3.89%。该股近5个交易日上涨7.57%，主力资金累计净流入1.9亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1.4亿元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219161748a6b63001&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219161748a6b63001&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0501845795.SGD","SG9999004220.SGD","LU1008478684.HKD","LU1226288170.HKD","LU1951186391.HKD","IE00BZ08YT58.USD","LU0140636845.USD","LU0072913022.USD","HK0000165453.HKD","LU1960683339.HKD","IE0008369823.USD","LU0067412154.USD","IE00BZ08YR35.GBP","IE00B5MMRT66.SGD","LU1226287792.SGD","LU1152091754.HKD","LU1226288253.USD","LU1328277881.USD","BK1521","LU0880133367.SGD","LU0314109678.HKD","LU1226287529.USD","LU1152091168.USD","IE00B031HY20.USD","IE00B543WZ88.USD","LU1993786604.SGD","BK1191","LU1813983027.USD","LU1807302812.USD","IE00BZ08YS42.EUR","LU2039709279.SGD","LU1226287875.USD","01093","LU0315179316.USD","BK1515","LU0326950275.SGD","IE0008368742.USD"],"gpt_icon":0},{"id":"1132338657","title":"石药集团 - Secukinumab注射剂的第三期临床试验获得初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1132338657","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132338657?lang=zh_cn&edition=full","pubTime":"2025-12-18 18:17","pubTimestamp":1766053020,"startTime":"0","endTime":"0","summary":"石药集团 - Secukinumab注射剂的第三期临床试验获得初步结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1152091168.USD","LU0314109678.HKD","LU0072913022.USD","LU0140636845.USD","LU1960683339.HKD","LU0326950275.SGD","LU1226287875.USD","BK1515","LU0880133367.SGD","IE00BZ08YR35.GBP","LU1813983027.USD","LU1807302812.USD","LU1008478684.HKD","LU1152091754.HKD","LU1226287529.USD","IE00BZ08YT58.USD","HK0000165453.HKD","LU1951186391.HKD","IE00BZ08YS42.EUR","LU1226288170.HKD","LU2039709279.SGD","LU1993786604.SGD","LU0067412154.USD","IE0008369823.USD","LU0315179316.USD","BK1521","IE0008368742.USD","SG9999004220.SGD","IE00B031HY20.USD","LU1226287792.SGD","LU1226288253.USD","BK1191","01093","IE00B5MMRT66.SGD","LU1328277881.USD","LU0501845795.SGD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2592971147","title":"石药创新再谋港股二次上市 首发募集资金使用率不足一半","url":"https://stock-news.laohu8.com/highlight/detail?id=2592971147","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592971147?lang=zh_cn&edition=full","pubTime":"2025-12-18 17:28","pubTimestamp":1766050106,"startTime":"0","endTime":"0","summary":"自2019年从石药集团（01093.HK）单独分拆至A股创业板上市后，石药创新制药股份有限公司（简称“石药创新”）日前再度向港交所递交上市申请，冲击“A+H”双重上市。回顾石药创新的发展历程，自2023年起公司多次收购石药集团旗下创新药资产，借此快速切入创新药赛道。战略转型的背后，逐渐频繁的资本运作也让公司与股东之间的内控治理成为市场关注的焦点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512183595542659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B5MMRT66.SGD","LU0072913022.USD","LU0315179316.USD","LU1152091168.USD","LU0140636845.USD","LU1226288253.USD","LU1152091754.HKD","LU1960683339.HKD","LU1328277881.USD","LU0314109678.HKD","BK1521","LU2039709279.SGD","LU1226288170.HKD","LU1226287875.USD","IE00B543WZ88.USD","BK1515","LU0501845795.SGD","IE00BZ08YR35.GBP","LU0326950275.SGD","IE00BZ08YS42.EUR","BK1191","LU1226287792.SGD","IE0008369823.USD","LU1813983027.USD","LU1993786604.SGD","LU0880133367.SGD","LU1951186391.HKD","01093","LU1008478684.HKD","IE00B031HY20.USD","HK0000165453.HKD","IE0008368742.USD","SG9999004220.SGD","IE00BZ08YT58.USD","LU0067412154.USD","LU1226287529.USD","LU1807302812.USD"],"gpt_icon":0},{"id":"2592513924","title":"创新药概念逆市上扬 石药集团(01093)午后升幅扩至近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592513924","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592513924?lang=zh_cn&edition=full","pubTime":"2025-12-18 13:21","pubTimestamp":1766035316,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念逆市上扬，石药集团 升5.98%，药明生物升1.97%，药明合联升1.56%，先声药业升1.51%，药明康德升1.28%。开源证券指出，当前纳入医保+商保的创新药大多处于未放量以及低基数阶段，随着医保支持创新药的政策红利持续释放，我们认为纳入双目录的创新药收入有望快速提升，患者有望持续受益，同时相关创新药企也随之迎来弹性增长。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971799","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1688375341.USD","IE00BZ08YR35.GBP","LU0501845795.SGD","LU1152091754.HKD","02268","LU0856984785.SGD","SG9999002562.SGD","LU0315179316.USD","IE0008369823.USD","LU1226287792.SGD","LU1813983027.USD","LU1242518931.SGD","IE00B031HY20.USD","BK1574","LU0181495838.USD","02096","LU1328277881.USD","LU0456827905.SGD","LU1226287875.USD","02359","IE00BZ08YT58.USD","LU1807302812.USD","LU0307460666.USD","LU0320764599.SGD","159992","IE00B543WZ88.USD","BK1191","LU0572944931.SGD","LU0140636845.USD","BK1589","BK1610","LU1008478684.HKD","LU0039217434.USD","IE00BZ08YS42.EUR","LU0348735423.USD","LU0051755006.USD","IE00B5MMRT66.SGD","LU0588546209.SGD","LU1046422090.SGD","LU0052750758.USD","LU1794554557.SGD","SG9999002463.SGD","BK1515","LU3063872942.SGD","02269","LU0348825331.USD","01093","06978","LU1242518857.USD","BK1583"],"gpt_icon":0},{"id":"2592910426","title":"12月17日港股药品及生物科技行业沽空数据盘点，信达生物、石药集团、三生制药沽空金额位居行业前三","url":"https://stock-news.laohu8.com/highlight/detail?id=2592910426","media":"证券之星APP","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592910426?lang=zh_cn&edition=full","pubTime":"2025-12-17 18:06","pubTimestamp":1765965972,"startTime":"0","endTime":"0","summary":"证券之星消息，12月17日港交所披露数据显示，当日港股药品及生物科技行业的159只个股中有83只被沽空，总沽空股数为1.01亿股，总沽空金额为15.15亿元（港元），而当日药品及生物科技行业的总成交金额为89.09亿元（港元），沽空比例为17.0%。从沽空金额来看，信达生物、石药集团、三生制药沽空金额位居行业前三，分别为1.65亿港元、1.52亿港元、1.2亿港元。沽空与卖空含义相同，即在并不持有股票的前提下，通过借入股票获得筹码进而卖出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217181708a45681d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217181708a45681d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0314109678.HKD","BK1161","BK1589","HK0000165453.HKD","LU0140636845.USD","LU2097828805.USD","LU1960683339.HKD","BK1515","LU1969619763.USD","LU2097828714.EUR","BK1583","LU1226288253.USD","LU1813983027.USD","BK1593","IE00BZ08YR35.GBP","LU1328277881.USD","LU0501845795.SGD","LU1226287792.SGD","LU1226288170.HKD","LU1993786604.SGD","LU1807302812.USD","IE00B543WZ88.USD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","LU1951186391.HKD","LU2097828474.EUR","LU2328871848.SGD","IE0008368742.USD","LU1152091754.HKD","IE0008369823.USD","SG9999004220.SGD","LU1226287529.USD","LU0326950275.SGD","LU0455707207.USD","LU2039709279.SGD","LU0315179316.USD","LU1008478684.HKD","IE00B031HY20.USD","LU2097828631.EUR","LU0502904849.HKD","LU0067412154.USD","LU2242644610.SGD","01801","01093","IE00B5MMRT66.SGD","LU1152091168.USD","LU0072913022.USD","01530","BK1521","BK1191"],"gpt_icon":0},{"id":"2592679039","title":"港股异动 | 石药集团(01093)尾盘涨近3% 贝派度酸片临床申请获受理 入局全新“非他汀类”降脂药","url":"https://stock-news.laohu8.com/highlight/detail?id=2592679039","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592679039?lang=zh_cn&edition=full","pubTime":"2025-12-17 15:32","pubTimestamp":1765956747,"startTime":"0","endTime":"0","summary":"消息面上，12月15日，据中国国家药品审评中心官网最新显示，石药集团旗下全资子公司石药集团欧意药业有限公司按化药注册分类3类申报的贝派度酸片临床申请获受理。值得一提的是，贝派度酸片原研药及仿制药均未尚未在国内上市。截至目前为止，国内已有甘李药业山东有限公司、江西施美药业、合肥立方制药、石药集团欧意药业4家药企申报的贝派度酸片临床申请均获受理，首仿之争已拉开帷幕。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01093","IE00BZ08YS42.EUR","LU1008478684.HKD","LU1993786604.SGD","LU1152091754.HKD","LU1226287792.SGD","BK1521","LU1807302812.USD","LU1951186391.HKD","IE00B031HY20.USD","LU2039709279.SGD","IE00BZ08YT58.USD","LU1152091168.USD","BK1191","LU1226288170.HKD","LU0315179316.USD","LU1328277881.USD","IE00BZ08YR35.GBP","LU1813983027.USD","LU0314109678.HKD","LU1226287529.USD","LU0880133367.SGD","LU0072913022.USD","LU0326950275.SGD","IE00B543WZ88.USD","IE0008369823.USD","IE00B5MMRT66.SGD","IE0008368742.USD","BK1515","LU1960683339.HKD","LU1226288253.USD","LU1226287875.USD","LU0501845795.SGD","LU0067412154.USD","HK0000165453.HKD","SG9999004220.SGD","LU0140636845.USD"],"gpt_icon":0},{"id":"2591632904","title":"英伟达连续布局13家企业，AI制药3个方向梳理（附列表）","url":"https://stock-news.laohu8.com/highlight/detail?id=2591632904","media":"投研大叔","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591632904?lang=zh_cn&edition=full","pubTime":"2025-12-13 19:40","pubTimestamp":1765626014,"startTime":"0","endTime":"0","summary":"今天介绍下AI制药，英伟达在过去2年投资13家AI药企，推出BioNeMo生物分子AI框架已经覆盖上百家药企，英硅智能ISM001-055进入临床III期，成为首个跨越临床II期的AI药物，从之前的布局到如今逐渐突破，商业价值正在逐渐被验证。从大叔个人来看，还有一些罕见病，由于患者少，研发不划算，而AI能快速低成本设计药物，让更多罕见病有药可治。近期热门文章HW组建医疗卫生军团，AI医疗爆发！","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213194757a4470c58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213194757a4470c58&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2505996681.GBP","IE00BDCRKT87.USD","LU0719512351.SGD","03759","LU2505996509.AUD","LU2191332357.HKD","NVDD","02228","IE000YTNTUN2.SGD","NVDY","IE0034235188.USD","SG9999004303.SGD","LU1988902786.USD","LU2237438978.USD","SNVD.UK","LU0308772762.SGD","06821","NVDU","LU2463028550.USD","NVDS","LU0444973449.USD","NVD3.UK","LU1642822529.SGD","NVDX","2NVD.UK","LU0320765059.SGD","LU1914381329.SGD","LU2602419157.SGD","NVIW.SI","LU1280957306.USD","01093","NVDA","02196","NVD","LU0157215616.USD","IE00BJJMRY28.SGD","06127","LU2860962120.EUR","SGXZ81514606.USD","LU2089284900.SGD","LU2592432038.USD","LU2065171311.SGD","LU2249611893.SGD","NVDS.UK","LU2420271590.USD","LU0274383776.USD","LU1145028129.USD","LU0158827948.USD","LU1839511570.USD","NVD2.UK","3NVD.UK","LU1496350171.SGD","LU2473716301.USD","IE000ITXATA3.USD","LU0096362180.USD","02359"],"gpt_icon":1},{"id":"2591635299","title":"瞩目，石药集团又一重磅药物新适应症获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2591635299","media":"北京药研汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591635299?lang=zh_cn&edition=full","pubTime":"2025-12-13 08:03","pubTimestamp":1765584214,"startTime":"0","endTime":"0","summary":"2025年12月12日，石药集团宣布，本集团全资子公司石药集团欧意药业有限公司开发的盐酸伊立替康脂质体注射液的新适应症获批上市。目前，石药集团的盐酸伊立替康脂质体注射液用于胰腺癌术后辅助治疗的关键注册III期临床试验正在进行中。随着石药集团该产品的第2项适应症获批上市，以及后续适应症临床试验的顺利推进，必将为广大胰腺癌患者提供新的治疗希望。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213081638a445d064&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213081638a445d064&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1226288253.USD","LU1960683339.HKD","IE00BZ08YS42.EUR","LU0501845795.SGD","HK0000165453.HKD","LU0072913022.USD","LU0315179316.USD","LU1226287875.USD","BK1191","IE00B031HY20.USD","LU1993786604.SGD","IE00B5MMRT66.SGD","LU1152091168.USD","LU2039709279.SGD","LU0140636845.USD","LU1226288170.HKD","LU1226287529.USD","BK1521","LU1226287792.SGD","IE0008368742.USD","LU1951186391.HKD","IE00B543WZ88.USD","SG9999004220.SGD","IE00BZ08YT58.USD","LU0314109678.HKD","LU1152091754.HKD","LU1807302812.USD","IE0008369823.USD","BK1515","IE00BZ08YR35.GBP","01093","LU1328277881.USD","LU1008478684.HKD","LU0880133367.SGD","LU0326950275.SGD","LU1813983027.USD","LU0067412154.USD"],"gpt_icon":0},{"id":"2590703195","title":"石药集团(01093)：多恩益®(盐酸伊立替康脂质体注射液)的新适应症获上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590703195","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590703195?lang=zh_cn&edition=full","pubTime":"2025-12-12 18:24","pubTimestamp":1765535073,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的盐酸伊立替康脂质体注射液的新适应症已获得中华人民共和国国家药品监督管理局上市批准。本次获批的适应症为该产品在中国获批的第二个适应症，亦是伊立替康脂质体注射液在国内首次获批用于胰腺癌一线治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团(01093)：多恩益®(盐酸伊立替康脂质体注射液)的新适应症获上市批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01093","LU1807302812.USD","SG9999004220.SGD","IE0008369823.USD","LU1226288170.HKD","LU1328277881.USD","LU0140636845.USD","IE00B031HY20.USD","LU1226287792.SGD","LU1152091168.USD","LU0067412154.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","BK1521","IE00BZ08YS42.EUR","LU2039709279.SGD","LU0326950275.SGD","LU0880133367.SGD","LU1226287529.USD","IE00BZ08YT58.USD","LU1226287875.USD","LU0501845795.SGD","LU1226288253.USD","LU0314109678.HKD","LU1813983027.USD","BK1515","LU1008478684.HKD","LU0072913022.USD","IE00BZ08YR35.GBP","LU0315179316.USD","LU1960683339.HKD","LU1993786604.SGD","LU1152091754.HKD","LU1951186391.HKD","BK1191","IE0008368742.USD","HK0000165453.HKD"],"gpt_icon":0},{"id":"2591963526","title":"每日卖空追踪 | 石药集团 12月12日卖空量成交861.6万股，卖空比例为8.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591963526","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591963526?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:30","pubTimestamp":1765528217,"startTime":"0","endTime":"0","summary":"石药集团北京时间12月12日，跌0.39%，卖空量成交861.6万股，较上一交易日减少64.93%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121216490195398ae6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121216490195398ae6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0315179316.USD","LU0314109678.HKD","LU1993786604.SGD","IE00BZ08YR35.GBP","LU1328277881.USD","HK0000165453.HKD","LU2039709279.SGD","LU1152091168.USD","BK1521","LU0326950275.SGD","LU1226287792.SGD","IE0008368742.USD","LU1226288253.USD","LU1226287875.USD","LU0501845795.SGD","IE00B5MMRT66.SGD","LU1226287529.USD","BK1515","LU0072913022.USD","LU0880133367.SGD","LU1008478684.HKD","IE00BZ08YS42.EUR","LU1152091754.HKD","IE00B031HY20.USD","LU1226288170.HKD","LU1813983027.USD","SG9999004220.SGD","IE00BZ08YT58.USD","IE00B543WZ88.USD","LU1807302812.USD","LU1960683339.HKD","LU0140636845.USD","BK1191","LU0067412154.USD","IE0008369823.USD","LU1951186391.HKD","01093"],"gpt_icon":0},{"id":"2590233595","title":"【券商聚焦】交银国际：创新药增量支付空间持续扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2590233595","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590233595?lang=zh_cn&edition=full","pubTime":"2025-12-12 09:02","pubTimestamp":1765501348,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，10月以来，内资通过港股通持有医药股的比例小幅下降，外资持仓整体平稳，内外资加大创新药布局的大方向不变。该机构指，本周医保+商保双目录落地，医保谈判新增品种成功率创近年新高，续约品种降价幅度相对温和。该机构认为商保资金的引入将为创新药支付带来重要增量资金，进一步优化多元支付体系。该机构看好医保新纳入品种/适应症在2026年的销售放量，以及首版商保目录的实际执行和支付情况。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971425","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518931.SGD","LU1993786604.SGD","LU1226287529.USD","LU2097828714.EUR","LU0456827905.SGD","LU1951186391.HKD","LU2328871848.SGD","02269","09688","LU2097828631.EUR","BK1161","LU0181495838.USD","LU0043850808.USD","LU0540923850.HKD","01093","SG9999002463.SGD","06978","06160","01801","LU0708995583.HKD","LU1969619763.USD","LU0516423091.SGD","LU0359202008.SGD","LU0359201612.USD","02142","159992","HK0000165453.HKD","LU0634319403.HKD","03329","02616","06185","LU0880133367.SGD","LU2039709279.SGD","LU0417516738.SGD","LU0502904849.HKD","01877","BK1588","SG9999004220.SGD","09926","LU0067412154.USD","IE00B0JY6N72.USD","LU1770034418.SGD","LU0348766576.USD","LU1961090484.USD","LU2778985437.USD","09995","01177","LU2097828557.USD","LU2242644610.SGD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2590800685","title":"新股消息 | 石药创新(300765.SZ)递表港交所 为全球最大化学合成咖啡因生产商","url":"https://stock-news.laohu8.com/highlight/detail?id=2590800685","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590800685?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:34","pubTimestamp":1765373692,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所12月10日披露，石药创新制药股份有限公司向港交所主板递交上市申请，中信证券为其独家保荐人。全球最大的咖啡因生产商。根据弗若斯特沙利文的资料，自2020年至2024年，按收入和出货量计，该公司始终保持着全球最大化学合成咖啡因生产商地位。财务资料收入2022年度、2023年度、2024年度及2025年截至7月31日止七个月，该公司收入分别约为28.38亿元、25.39亿元、19.81亿元、12.41亿元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","LU1951186391.HKD","LU0314109678.HKD","LU0326950275.SGD","BK1191","BK1515","LU1993786604.SGD","IE00BZ08YS42.EUR","IE0008369823.USD","LU1328277881.USD","IE0008368742.USD","LU0072913022.USD","IE00B543WZ88.USD","LU0140636845.USD","IE00BZ08YT58.USD","LU1226287529.USD","01093","LU1152091168.USD","IE00BZ08YR35.GBP","IE00B031HY20.USD","LU0067412154.USD","LU0501845795.SGD","LU0315179316.USD","LU1226287875.USD","LU1226287792.SGD","LU1807302812.USD","BK1521","LU1813983027.USD","SG9999004220.SGD","LU0880133367.SGD","300765","BK0226","HEXmain","LU1152091754.HKD","IE00B5MMRT66.SGD","LU1226288253.USD","LU1008478684.HKD","LU1226288170.HKD","LU1960683339.HKD","LU2039709279.SGD"],"gpt_icon":0},{"id":"2590258591","title":"石药集团(01093)：重组全人源抗ACTRIIA / IIB单克隆抗体(JMT206) 在美国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590258591","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590258591?lang=zh_cn&edition=full","pubTime":"2025-12-10 18:20","pubTimestamp":1765362040,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的重组全人源抗ActRIIA/IIB单克隆抗体(该产品)已获美国食品药品监督管理局批准，可在美国开展临床试验。同时，该产品亦可协助GLP-1受体激动剂实现更高质量的减重效果。本次获批的临床适应症为肥胖或超重合并至少一种体重相关合并症人群的体重管理。临床前研究显示，该产品表现出较高的生物利用度以及良好的有效性和安全性，具有较高的临床开发价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团(01093)：重组全人源抗ACTRIIA / IIB单克隆抗体(JMT206) 在美国获临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226288253.USD","LU1960683339.HKD","IE00BZ08YS42.EUR","LU0501845795.SGD","HK0000165453.HKD","LU0072913022.USD","LU0315179316.USD","LU1226287875.USD","BK1191","IE00B031HY20.USD","LU1993786604.SGD","IE00B5MMRT66.SGD","LU1152091168.USD","LU2039709279.SGD","LU0140636845.USD","LU1226288170.HKD","LU1226287529.USD","BK1521","LU1226287792.SGD","IE0008368742.USD","LU1951186391.HKD","IE00B543WZ88.USD","SG9999004220.SGD","IE00BZ08YT58.USD","LU0314109678.HKD","LU1152091754.HKD","LU1807302812.USD","IE0008369823.USD","BK1515","IE00BZ08YR35.GBP","01093","LU1328277881.USD","LU1008478684.HKD","LU0880133367.SGD","LU0326950275.SGD","LU1813983027.USD","LU0067412154.USD"],"gpt_icon":0},{"id":"2590610584","title":"每日卖空追踪 | 石药集团 12月10日卖空量成交858.2万股，卖空比例为8.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590610584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590610584?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:30","pubTimestamp":1765355418,"startTime":"0","endTime":"0","summary":"石药集团北京时间12月10日，涨3.19%，卖空量成交858.2万股，较上一交易日减少69.68%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121016323495353c3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121016323495353c3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0314109678.HKD","SG9999004220.SGD","LU1226287792.SGD","LU0315179316.USD","BK1521","IE0008369823.USD","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU0067412154.USD","01093","LU1152091168.USD","IE00BZ08YT58.USD","HK0000165453.HKD","IE00BZ08YS42.EUR","LU1807302812.USD","LU1008478684.HKD","LU1226287529.USD","LU0880133367.SGD","LU1993786604.SGD","IE00B543WZ88.USD","LU1960683339.HKD","LU1152091754.HKD","LU1226288170.HKD","BK1191","IE00B5MMRT66.SGD","LU1226287875.USD","LU1328277881.USD","LU2039709279.SGD","LU0140636845.USD","LU0326950275.SGD","LU1951186391.HKD","LU1226288253.USD","IE0008368742.USD","LU0501845795.SGD","LU1813983027.USD","LU0072913022.USD","BK1515"],"gpt_icon":0},{"id":"2590309346","title":"港股异动 | 石药集团(01093)尾盘涨超3% 司美格鲁肽注射液第二项上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2590309346","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590309346?lang=zh_cn&edition=full","pubTime":"2025-12-10 15:17","pubTimestamp":1765351061,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，石药集团尾盘涨超3%，截至发稿，涨2.92%，报7.75港元，成交额5.15亿港元。消息面上，12月8日，石药集团发布公告，公司附属公司石药集团百克(山东)生物制药股份有限公司开发的司美格鲁肽注射液的第二项上市许可申请已获中华人民共和国国家药品监督管理局受理。此前，该产品拟用于成人2型糖尿病血糖控制的适应症上市许可申请已于2025年8月获国家药监局受理。公告称，本次申请基于一项Ⅲ期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 石药集团(01093)尾盘涨超3% 司美格鲁肽注射液第二项上市许可申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1008478684.HKD","LU1152091168.USD","IE00BZ08YT58.USD","LU1328277881.USD","LU1807302812.USD","01093","LU0501845795.SGD","LU1993786604.SGD","LU1226288253.USD","LU1226287792.SGD","LU0072913022.USD","LU0326950275.SGD","LU0880133367.SGD","IE00B543WZ88.USD","LU1152091754.HKD","LU1960683339.HKD","LU0140636845.USD","HK0000165453.HKD","LU0067412154.USD","BK1515","LU1226287529.USD","SG9999004220.SGD","LU1951186391.HKD","IE00BZ08YR35.GBP","BK1521","LU0315179316.USD","LU1813983027.USD","LU1226288170.HKD","IE00B5MMRT66.SGD","LU1226287875.USD","IE00B031HY20.USD","LU2039709279.SGD","IE00BZ08YS42.EUR","IE0008369823.USD","IE0008368742.USD","LU0314109678.HKD","BK1191"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":0.0705},{"period":"1month","weight":0.0832},{"period":"3month","weight":-0.1624},{"period":"6month","weight":0.0926},{"period":"1year","weight":0.7642},{"period":"ytd","weight":0.7642}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0322},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.3006},{"period":"ytd","weight":0.2807}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事生产及销售药品的投资控股公司。该公司通过三个分部运营其业务。成药分部从事研发、生产及销售药品以及授权业务。原料产品分部从事生产及销售粉状维生素C及抗生素产品。功能食品及其他分部从事制造及销售功能食品产品（包括咖啡因食物添加剂、无水葡萄糖、阿卡波糖及维生素C含片）、提供医疗服务及其他。该公司的产品治疗领域包括神经系统、抗肿瘤、抗感染、心血管、呼吸系统、消化代谢等其他领域。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.516129,"avgChangeRate":0.005459},{"month":2,"riseRate":0.741935,"avgChangeRate":0.096733},{"month":3,"riseRate":0.483871,"avgChangeRate":0.020489},{"month":4,"riseRate":0.612903,"avgChangeRate":0.062074},{"month":5,"riseRate":0.612903,"avgChangeRate":0.047434},{"month":6,"riseRate":0.322581,"avgChangeRate":0.003636},{"month":7,"riseRate":0.375,"avgChangeRate":0.009082},{"month":8,"riseRate":0.4375,"avgChangeRate":0.010009},{"month":9,"riseRate":0.5,"avgChangeRate":0.000153},{"month":10,"riseRate":0.5625,"avgChangeRate":0.010484},{"month":11,"riseRate":0.46875,"avgChangeRate":0.00638},{"month":12,"riseRate":0.5,"avgChangeRate":-0.01418}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}